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Background and objectives 
 Due to the annual reformulation of the influenza vaccine composition estimates of the 
vaccine effectiveness (VE) are required every season.  
 A Portuguese influenza surveillance system is in place, and data obtained by this system 
may be used to evaluate VE (compared to studies specifically designed to this purpose).  
 
This study intends to evaluate the feasibility of using the national influenza 
surveillance system for monitoring the influenza VE (MonitorEVA). 
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•Standardized questionnaire: one respondent by household 
(proxy for the rest of the household members).   
CASES (ILI+) 
positive for any influenza virus 
CONTROLS (ILI-) 
negative for any influenza virus 
 
Select ILI cases (clinical signs and symptoms) 
  
Test Negative Design 
(TND) 
Sample of GP/ emergency room 
Data collection by the GP 
1. Standardized questionnaire: 
2. Nasopharyngeal swab 
Laborayory analysis 
(RT-PCR / Culture) 
Screening Method 
(SM) 
ECOS sample 
Data collection by  CATI 
VC CASES (ILI +) 
VC  COMMUNITY 
CONTROLS 
Data analysis 
Weighted by sex and age of the Portuguese population 
A sample of 1074 households 
(stratified by region homogeneous allocation)  
selected from  a dual sample frame- random digit dialing 
Statistical analysis 
VE =1 – OR being vaccinated in cases versus 
controls adjusted for confounders by logistic 
regression 
Statistical analysis 
 
PPV= Proportion of vaccinated community 
PCV Proportion of vaccinated cases 
Farrington method to adjust for age group 
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FIGURE 1. SEASONAL VACCINE EFFECTIVENESS AGAINST INFLUENZA ESTIMATED USING TND AND SM 
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MonitorEVA EuroEVA* IMOVE** 
2008/09  
(65 and plus) 
VE 23,6 -3,0 59,0 
IC95% (-87; 69) (-316; 75) (15; 80) 
2009/10  
(pandemic vaccine) 
VE 67,0 72,0 
IC95% (-60; 93) (46; 86) 
2010/11 
(seasonal vaccine) 
EV ajustada 44,0 58,2 52,0 
IC95% (-3,6; 69,3) (-61; 89) (30; 67) 
2011/12 
(seasonal vaccine) 
EV ajustada 5,0 48,8 25,0 
IC95% (-80,9; 50,2) (0; 74) (6; 47) 
TABLE  1. ADJUSTED VACCINE EFFECTIVENESS AGAINST INFLUENZA: COMPARISON 
BETWEEN MONITOREVA AND OTHER TND AD-HOC STUDIES 
*EuroEVA: National study to estimate VE 
**I-MOVE: European multicentric case-control study 
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 SM estimates were in accordance to the TND ones but for the 
majority of the SM VE was lower than the TND. 
 
 Sample size and data quality are sufficient to obtain crude VE 
estimates with statistical significance (if VE is higher than 50%), however 
allowing less precise estimates.  
 
 The surveillance data allowed the VE monitoring indicating if the VE 
was higher than 70% and less than 50%. 
Main messages 
 Improvement of data quality in the surveillance program seems a 
potential way of improving precision and closing the gap between the two 
methods proposed.  
 
 Despite being less precise data from national influenza surveillance 
program seem to be a less expensive and adequate alternative to assess 
vaccine effectiveness. 
